Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1997 1
1998 3
2000 1
2009 1
2016 2
2017 2
2018 2
2019 1
2020 2
2021 3
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis.
Mukherjee S, Kanhai K, Kauffman D, Martin R, Paige JS, Ghosh A, Kannan H, Shupo F, Fajgenbaum DC. Mukherjee S, et al. Among authors: kanhai k. Leukemia. 2022 Oct;36(10):2539-2543. doi: 10.1038/s41375-022-01690-2. Epub 2022 Sep 29. Leukemia. 2022. PMID: 36175555 Free PMC article. No abstract available.
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.
Gritti G, Raimondi F, Bottazzi B, Ripamonti D, Riva I, Landi F, Alborghetti L, Frigeni M, Damiani M, Micò C, Fagiuoli S, Lorini FL, Gandini L, Novelli L, Morgan JP, Owens BMJ, Kanhai KJK, Reljanovic GT, Rizzi M, Di Marco F, Mantovani A, Rambaldi A. Gritti G, et al. Among authors: kanhai kjk. Leukemia. 2021 Sep;35(9):2710-2714. doi: 10.1038/s41375-021-01299-x. Epub 2021 May 24. Leukemia. 2021. PMID: 34031531 Free PMC article. No abstract available.
Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.
Kanhai KMS, Nij Bijvank JA, Wagenaar YL, Klaassen ES, Lim K, Bergheanu SC, Petzold A, Verma A, Hesterman J, Wattjes MP, Uitdehaag BMJ, van Rijn LJ, Groeneveld GJ. Kanhai KMS, et al. CNS Neurosci Ther. 2019 Jun;25(6):697-703. doi: 10.1111/cns.13096. Epub 2019 Feb 12. CNS Neurosci Ther. 2019. PMID: 30756475 Free PMC article. Clinical Trial.
Administration of oxathridine, a first-in-class histamine-3 receptor partial agonist in healthy male volunteers: Central nervous system depression and pseudo-hallucinations.
Dijkstra FM, Zuiker RGJA, Heuberger JAAC, Kanhai KMS, De Kam M, Duvauchelle T, Lecomte JM, Labeeuw O, Landais L, Ligneau X, Robert P, Capet M, Schwartz JC, van Gerven JMA. Dijkstra FM, et al. Among authors: kanhai kms. Br J Clin Pharmacol. 2024 Jan;90(1):321-335. doi: 10.1111/bcp.15910. Epub 2023 Oct 11. Br J Clin Pharmacol. 2024. PMID: 37724688 Clinical Trial.
23 results